Just a few months after upgrading its portfolio of recharge-free spinal cord stimulators with FDA approval for a new version of the technology, Abbott has done the same for its line of rechargeable neurostimulation devices.

Pfizer, looking to be the king in respiratory syncytial virus vaccines and therapeutics, is going back to scoop up one therapy that was left on the table earlier this summer when the pharma giant acquired ReViral and its RSV portfolio.

Three days after appointing its next CEO, Bionomics had to break the news to investors that its lead asset has flunked a phase 2 trial in acute social anxiety disorder (SAD).

With the latest in a string of acquisitions, Velocity Clinical Research is laying claim to the title of largest dedicated research site organization in the world.

As the EU’s new system for regulating medical devices takes effect, some medtech companies are finding the process of securing new authorizations for their previously authorized devices overwhelming—and, in some cases, not worth the trouble.

After signing a collaboration with fellow French company Innate Pharma in 2016 to develop natural killer (NK) cell engagers, Sanofi is paying 25 million euros upfront for a second order.

If Astellas needed further proof its $1.3 billion oncology bet was worth the price tag, the second successful phase 3 trial in a month should do the trick.

Ahead of the upcoming separation of two of Medtronic’s business units into a standalone company, some of the medtech giant’s peers are reportedly considering adding the sloughed-off segments to their own portfolios.

In these financially straitened times, biotechs need to be increasingly ruthless about which programs they can afford to keep funding. For oncology-focused Sonnet BioTherapeutics, that means halting work on a bispecific molecule while seeking partners for two others.

Eli Lilly has followed in the footsteps of many Big Pharma contemporaries by penning its own $730 million deal with Sosei Heptares to work on small molecules that modulate G protein-coupled receptor (GPCR) targets.